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Abstract 
The need to address substance use among people with psychosis has been well established. 
However, treatment studies targeting substance use in this population have reported mixed 
results. Substance users with psychosis in no or minimal treatment control groups achieve 
similar reductions in substance use compared to those in more active substance use 
treatment, suggesting a role for natural recovery from substance use. This meta-analysis 
aims to quantify the amount of natural recovery from substance use within control groups 
of treatment studies containing samples of psychotic substance users, with a particular 
focus on changes in cannabis use. A systematic search was conducted to identify substance 
use treatment studies. Meta-analyses were performed to quantify reductions in the 
frequency of substance use in the past 30 days. Significant but modest reductions (mean 
reduction of 0.3-0.4 SD across the time points) in the frequency of substance use were 
found at 6 to 24 months follow up. The current study is the first to quantify changes in 
substance use in samples enrolled in no treatment or minimal treatment control conditions. 
These findings highlight the potential role of natural recovery from substance use among 
individuals with psychosis, although they do not rule out effects of regression to the mean. 
Additionally, the results provide a baseline from which to estimate likely changes or needed 
effects sizes in intervention studies. Future research is required to identify the processes 
underpinning these changes, in order to identify strategies that may better support self-
management of substance use in people with psychosis. 
 
Keywords:  Cannabis; self-management; psychosis; natural recovery; substance use; 
comorbidity 
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1.0 Introduction 
 Rates of psychoactive substance use in psychotic populations are much higher than 
those in the general population, and this use has been associated with detrimental 
psychological, social, and physical effects (Hjorthøj et al., 2009). These observations have led 
to concerted efforts to develop effective psychological treatments to reduce this 
consumption and its associated harm. However, the results of clinical trials on these 
treatments have been mixed (Hjorthøj et al., 2014; Hjorthøj et al., 2009; Kavanagh et al., 
2004; Madigan et al., 2013).  
 An issue with efforts to address this problem is the extent of change in control 
conditions. Similar reductions in substance use among people with psychosis are often seen 
after these treatments and in assessment only, minimal treatment or treatment-as-usual 
control conditions (Kavanagh and Mueser, 2007). A recent review of treatment studies of 
first episode psychosis groups, including five with and nine without specialised substance 
use treatment, found that participants were able to reduce their average consumption, 
regardless of whether they received specialist substance use treatment or not (Wisdom et 
al., 2011). Receipt of specialised substance use treatment did not result in larger reductions 
or better rates of abstinence (Wisdom et al., 2011). In fact, follow up research on patients 
with psychosis not treated for substance use (Baeza et al., 2009; Caspari, 1999; Lambert et 
al., 2005; Wade et al., 2006) have reported abstinence rates of 21%—63% over 15 months 
to 5 years (Caspari, 1999; Lambert et al., 2005; Wade et al., 2006).  
These results highlight the potential role of natural recovery from substance use in 
psychotic populations (Wisdom et al., 2011). While these improvements may reflect 
effective self-management of substance use, they may also reflect regression to the mean (if 
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participants entered treatment during a period of unusually heavy substance use). 
Observations of reduced consumption in the first month after a negative experience from 
cannabis, of similar or greater size as in the general population are consistent with both of 
these suggestions (Green et al., 2007). Regardless of the phenomenon’s determinants, 
clarifying its extent is important in the interpretation of clinical outcomes and in planning 
treatment trials.  
A gap in current knowledge is that research is yet to quantify the extent of untreated 
improvements from substance use that occurs. Accordingly, the current study conducts a 
meta-analysis that aims to quantify the reductions in the frequency of substance use that is 
achieved within control groups of treatment studies targeting psychotic clients. It focuses 
particularly on changes in use of cannabis, the most commonly used illicit substance 
worldwide (United Nations Office on Drugs and Crime, 2014), and a substance that has been 
linked to increased risk of psychotic symptomatic exacerbations and relapse (Hides et al., 
2006). 
2.0 Methods 
Electronic searches were performed in January 2016 to find studies that included a 
control group and had tested treatment for current cannabis use in people with both a 
psychotic and substance use disorder. The searches used title, abstract and keywords of 
Medline, PsycINFO, Psychology Journals, and Psychology Subject Corner. The search was 
expanded to include other substances (due to limited results for cannabis alone), giving the 
search terms: (cannabis OR marijuana OR marihuana OR addiction OR abuse OR substance 
OR cocaine OR dual diagnosis OR comorbid OR comorbidity OR co-occurring) AND (psychosis 
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OR psychoses OR schizophren* OR schizotypal OR psychotic OR bipolar) AND (treatment OR 
randomi* control).   
Potential studies were evaluated for inclusion in this review, based on whether they: 
(a) provided data that allowed the calculation of pre-post effect sizes in a group of 
participants receiving inactive (e.g. waitlist) or routine care (excluding substance use 
treatment); (b) were in English; (c) did not comprise case studies or personal accounts. In 
order to report results on a single measure, we restricted the studies to those reporting 
days of substance use in the past 30 (or equivalent). If this data was not reported, attempts 
were made to contact the authors to obtain it. Due to limited number of trials, studies that 
had some participants who used substances (including cannabis) and only reported days of  
substance use (as a global measure) were also included. However, studies that were solely 
focused on alcohol or nicotine were excluded. 
The examination of effect sizes used Comprehensive Meta-Analysis (Borenstein et 
al., 2005). A random effects model was applied as it is a more conservative approach and is 
the appropriate method to use when samples or treatments are different, irrespective of 
whether significant heterogeneity is demonstrated (Borenstein et al., 2009). Effects are 
reported as standardised mean differences (Cohen’s d). Analyses of degree of change 
require estimates of test-retest correlations of the measures, or reported analyses of 
changes within groups. While Timeline Followback assessments of cannabis use can have a 
7-14 day test-retest reliability of 0.92 (Robinson et al., 2014), the reliability of the 3-12 
month assessments of cannabis use in the current trials is unknown. As a result an estimate 
of 0.70 was used for the primary analyses. Sensitivity analyses were also undertaken using 
test-retest correlations of .60 and .80.  Where means and standard deviations were 
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reported on different sample sizes at baseline and follow-up, the follow-up sample size for 
the analysis was used, estimating baseline scores for retained participants using the full 
sample. Sample-weighted mean days of use at baseline, post and follow-up assessments are 
displayed in Appendix A. 
3.0 Results 
The search elicited 1,492 articles (See Figure 1). Based on reviews in the area, no 
relevant articles appeared to be missed (e.g., Hjorthøj et al., 2014; Wisdom et al., 2011). A 
final decision on the inclusion of all papers was made after reading the full paper. Any 
ambiguous articles were reviewed until consensus was reached. Some studies reported 
substance use in general, but reported the number of cannabis users in the sample and 
were therefore retained in this study. 
******************** Insert Figure 1 ***************************** 
Of the 30 papers identified, those by Lehman, Herron, Schwartz, & Myers (1993), 
Hellerstein, Rosenheck, & Miner (1995), Baker et al. (2006; 2002), James et al. (2004) and 
Hjorthøj et al (2013) were excluded due to an inability to estimate days of cannabis use in 
the previous 30. A further 16 studies were excluded due to an inability to calculate a within-
group effect size from the data provided (Bellack et al., 2006; Bonsack et al., 2011; Burman, 
1997; Calsyn et al., 2005; Castle and Ho, 2003; Clark, 2001; Craig et al., 2008; Drebing et al., 
2005; Haddock et al., 2003; Hellerstein et al., 2001; Herman et al., 1997; Kavanagh et al., 
2004; Martino et al., 2006; Ries et al., 2004; Sigmon and Higgins, 2006; Weiss et al., 2007). 
Essock et al., (2006) was included after consensus by all authors that the standard case 
management provided to participants was part of routine care and was unlikely to have 
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included extensive substance use treatment. The final eight articles meeting full inclusion 
criteria are described in Table 1 and the methodological details in Table 2.      
******************** Insert Table 1 & 2 ***************************** 
Over 6 months, weighted mean days fell from 13.2 to 10.6 across 6 studies (a 
summary of the mean effects is provided in Appendix A). Using a test-retest correlation of 
.70, the random effects meta-analysis gave a mean reduction of 0.332 SD (p < .001; Figure 
2), and 80 missing studies would be required to take the result to p > .05.  There was no 
significant heterogeneity (Q(5) = 10.23, p  = .069). Sensitivity analyses using test-retest 
correlations of .60 (-.330, CI: -.460 to -.200) and .80 (-.332, CI: -.461 to -.204) made little 
difference to the obtained effect. 
Over 10-12 months, the random effects meta-analysis produced a mean reduction of 
0.328 SD over 7 studies (p < .001; Figure 3), and 82 missing studies would be required for 
the result to reach p > .05.  Heterogeneity fell short of significance (Q(6) = 7.91, p  = .245). 
Sensitivity analyses using test-retest correlations of .60 (-.337, CI: -.433 to -.241) and .80 (-
.318, CI: -.422 to -.215) again had little impact.  
******************** Insert Figures 2, 3 and 4 about here*********************** 
The four studies with data to 24 months had a mean reduction of 0.450 SD (p < .001; 
Figure 4), and 81 missing studies would be required to take the result to p > .05.  There was 
significant heterogeneity in this subgroup (Q(3) = 22.99, p  < .001). Sensitivity analyses using 
test-retest correlations of .60 (-.452, CI: -.723 to -.182) and .80 (-.444, CI: -.699 to -.189) did 
not substantially change the results.  
A review of the methodological quality of the control group data is in Table 2. 
Retention rates for 4 of the studies were at least 70% at 6 months, which is an overall 
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strength of the studies. Another strength was that 5 had single-blind follow-up. All of the 
studies verified substance use disorder and substance use across the studies using 
structured methods with 3 studies verifying substance use with urine or hair analysis. A 
significant weakness of the results being interpreted as natural recovery was the limited 
information pertaining to substance use interventions within standard case management. 
Every study had at least one significant issue that should induce caution in the 
interpretation of its results.  
4.0 Discussion  
The current review found significant reductions in the frequency of cannabis use 
among users with psychosis. At 6 months, patients were only using 11 days per month with 
an average reduction of 0.3 SD. This result provides the degree of change in treatment trials 
potentially due to natural recovery and the effect required to enhance future specialised 
substance use treatment trials. The results remained modest over time, at 10-12 months an 
average reduction of 0.3 SD and 24 months 0.4 SD. These results need to be interpreted 
with caution due to the methodological limitations outlined.  
While treatment of cannabis use in people with psychosis has limited differential 
effectiveness above self-management, results of the current study demonstrate that on 
average, this population may have potential to self-manage their consumption if they are 
sufficiently motivated to do so. It is possible that part or all of the observed changes were 
due to regression to the mean, although the maintenance of the changes over as long as 24 
months suggests concerted self-management rather than statistical aberration. Further 
research is also needed to determine the extent that the observed improvements across 
studies have substantial functional or clinical impact.  
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In our recent review examining reductions in days of cannabis use within control 
groups of treatment studies we found that average weighted mean days of use in the 
previous 30 days fell from 24.8 to 18.6 at 2-4 months across nine studies (Rebgetz et al., 
2015b). A meta-analysis could only be undertaken to 2-4 months (due to limited studies 
providing data on longer follow up periods), which showed an average reduction of .540 SD, 
which was highly significant (p  < .001). While the reduction over 6 months in the psychosis 
samples (0.33 SD) was 40% less than non-psychotic samples obtained over 2-4 months (0.54 
SD), the higher level of  baseline consumption frequency in the non-psychotic group may 
have allowed greater regression to the mean. However, due to different time periods a 
direct comparison between those with and without psychosis cannot be made.  
Research into natural recovery from substance misuse in the general population has 
provided valuable insights into recovery strategies for enhancing treatments. Since at least a 
partial average recovery appears to also occur in people with psychosis, a similar research 
approach may also identify new ways to support self-management of substance use among 
this population. A handful of studies have attempted to explore this area, although due to 
their limited number and methodological limitations,  further well-designed research is 
required (Rebgetz et al., 2015a).  
 An important limitation to the current study was the need to exclude 22 papers that 
did not allow a calculation of effect sizes on the frequency of cannabis or other substance 
use in the previous 30 days. While this criterion ensured comparability across studies, the 
substantial loss of potential studies highlighted the need for common minimum data 
reporting in treatment trials across this field. Other methodological limitations include the 
fact that only one author conducted the main literature search, although any issues on 
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inclusions were referred to all authors for collective decision, and no additional papers were 
identified from reviews. The presence of differing psychiatric diagnoses or problem 
substances, and a lack of control for symptom severity or for multiple substance use also 
raise issues. The Essock et al., (2006) paper was included despite some substance use 
treatment being provided to the participants, but the study showed less change than most 
others and therefore its inclusion did not inflate the size of the obtained effect. Several 
other studies involved treated samples in which informal substance use interventions may 
have occurred, although specialist treatment for substance use was not provided. Retention 
rates across the studies appeared to be adequate, although it is possible that participants 
with more severe substance use problems were more likely to drop out, which may have 
inflated positive outcomes. However if this did occur, it is also likely in future research and 
clinical applications. Lastly, most studies only included self-reports of substance use without 
urine drug screening. Urine drug screening may have assisted to verify self-reports of 
cannabis use. However, our previous study, reported high levels of agreement between 
cannabis immunoassays or gas chromatography/mass spectrometry and self-reported 
cannabis use (Cohen’s kappa = 0.90), which suggests that self-reports are reliable (Hides et 
al., 2006; Rebgetz et al., 2014). While inflation of the currently observed effects due to 
reporting biases cannot entirely be ruled out, this research on the reliability of self-reports 
suggests that any such influence is likely to be minor. 
This is the first meta-analysis to explore changes in cannabis/substance use in 
minimal or no treatment control conditions of clinical trials targeting substance use in 
psychotic patients. Its findings are important: It shows that modest but well-maintained 
reductions in the frequency of average cannabis use can be seen in patients with psychosis 
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who did not receive specialist substance use treatment. A more detailed understanding of 
strategies that are perceived to assist self-control of substance use in these populations 
could inform the development of new more effective substance use treatment.  
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Table 1.  Methodological characteristics of cannabis and other substance use treatment trials in psychotic populations: Studies reporting the days of cannabis or other 
substance use in the past 30 days  
Author (Date) Sample 
Type at 
Baseline 
Disorder Country Control Group Measure Substance Retention rates 
        
Drake et al., 1998  OP 
 
SCZ/SA/BP  
SUD 
US SCM, team approach in 
community targeting MH & 
SUD 
 
Days of use in past 6 months 
 
Illicit 91% at 3 years 
Edwards et al., 2006 OP 
 
PDNOS  
CUD 
AU 10 week group  
psychoeducation on 
psychosis 
Percent days used Cannabis in 
past 4 weeks 
Cannabis 71% at 6-months 
Essock et al., 2006 OP 
HM  
SCZ/ SA/BP/MD 
SUD 
US SCM, team approach in 
community targeting MH & 
SUD 
Number of days of drug use in 
past 6 months  
Illicit 96% at 3 years 
Morse et al., 2006 OP 
HM 
 
SCZ/PDNOS/BP/ 
MD/SA  
SUD 
US Shown a list of MH & 
SU treatment agencies 
 
Days used substances 
In past 90 
Illicit 
(19% Cannabis) 
88% at 2 years 
Barrowclough et al., 
2010 
OP  
 
SZ/SA  
SUD 
UK Psychiatric care 
(medication, case 
management) 
Proportion of days abstinent 
from main substance in past 90 
days 
Any (50% 
Cannabis) 
72% at 2 years 
Morrens et al., 2011 IP 
 
PDNOS  
SUD 
BE TAU focused on psychotic 
symptoms 
Frequency of cannabis use over 
past 30 days 
Illicit (60% 
Cannabis) 
71% at 3-months 
20% at 1 year 
Smeerdijk et al., 2012 OP 
 
SCZ/PDNOS  CUD NL Routine family support Mean days of cannabis use in 
the past 90 
Cannabis 86% at 10-months 
Madigan et al., 2013  OP 
 
PDNOS  
SUD 
IE Multidisciplinary care, 
antipsychotic treatment 
Frequency of cannabis use over 
past 30 days 
Cannabis 76% at 3-months 
66% at 1 year 
AU: Australia  BE: Belgium    IE: Ireland  NL: The Netherlands  US: United States of America 
IP: Inpatients  HM: Homeless/unstably housed  OP: Outpatients 
BP: Bipolar  MD: Major Depression    SCZ: Schizophrenia/schizophreniform  SA: Schizoaffective  
PDNOS: Psychotic Disorder Not Otherwise Specified/psychotic disorder spectrum  
SUD: Substance Use Disorder (abuse or dependence)  CUD: Cannabis Use Disorder (abuse or dependence)  
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Table 2.  Methodological review of control treatments from the included randomised controlled trials 
Study Symptom/Diagnostic 
Measure 
Treatment received by Controls Follow-up retention Intention to treat 
(and management of 
missing data) 
Single-Blind 
follow-up 
      
Drake et al., 1998  SUD: SCID 
SU: TLFB, ASI, 
Urinalysis 
Standard Case Management NR NR NR 
Edwards et al., 2006 SUD: SCID   
CU: CASUAS, self-
report 
10 individual PE sessions focused on 
psychosis, avoiding explicit discussion of 
cannabis 
Standard Case Management 
74% to 6 mths Yes 
(LOCF) 
Yes 
Essock et al., 2006 SUD: SCID 
SU: TLFB, ASI, 
urinalysis 
Standard Case Management:  NR NR NR 
Morse et al., 2006 SUD: SCID 
CU: self-report 
NR 
Between 0.39 and 0.16 contacts per month in 
regards to substance abuse treatment 
NR Yes 
(NR) 
No 
Barrowclough et al., 2010 SUD: SCID 
CU: TLFB self-report, 
hair analysis (25%) 
Standard Case Management 91% to 6 mths 
71% to 24 mths 
Yes 
(Secondary analyses) 
Yes 
Morrens et al., 2011 SUD: Clinical 
interview 
CU: ASI, self-report 
Standard Case Management with no formal 
for substance use 
71% to 6 mths 
20% to 12 mths 
Yes 
(Carried previous data 
forward) 
Open label 
Smeerdijk et al., 2012 SUD: Clinial interview 
CU: TLFB 
Meetings with a family therapist. No formal 
skills provided 
77% to 10 mths Yes (means of the 
multiple imputation 
method) 
Yes 
Madigan et al., 2013  SUD: SCID 
CU: ASI 
Standard care. Five participants previous 
addiction counselling (more than 12 months 
ago) 
76% to 3 mths 
65% to 12 mths 
Yes (NR) Yes 
SUD: Substance Use Disorder   CU: Cannabis use   SU: Substance use
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title (n=171) 
Articles screened on the basis of 
abstracts (n=74) 
Articles excluded (n=22) 
  Inability to estimate days of    
  cannabis use in the past 30 
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Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.578 0.132 0.018 -0.838 -0.319 -4.371 0.000
Edwards et al., 2006 -0.247 0.161 0.026 -0.562 0.067 -1.542 0.123
Essock et al., 2006 -0.138 0.078 0.006 -0.291 0.016 -1.759 0.079
Morse et al., 2006 -0.370 0.114 0.013 -0.595 -0.146 -3.239 0.001
Barrowclough et al., 2010 -0.358 0.066 0.004 -0.487 -0.230 -5.456 0.000
Morrens et al., 2011 -0.449 0.257 0.066 -0.952 0.055 -1.746 0.081
-0.332 0.066 0.004 -0.462 -0.202 -5.004 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
 
18 
 
Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.516 0.130 0.017 -0.772 -0.261 -3.959 0.000
Essock et al., 2006 -0.254 0.079 0.006 -0.409 -0.099 -3.215 0.001
Morse et al., 2006 -0.233 0.112 0.013 -0.452 -0.013 -2.074 0.038
Barrowclough et al., 2010 -0.416 0.069 0.005 -0.551 -0.281 -6.031 0.000
Morrens et al., 2011 -0.289 0.299 0.089 -0.874 0.297 -0.966 0.334
Smeerdijk et al., 2012 -0.387 0.180 0.032 -0.739 -0.035 -2.155 0.031
Madigan et al., 2013 0.000 0.207 0.043 -0.406 0.406 0.000 1.000
-0.328 0.052 0.003 -0.431 -0.226 -6.292 0.000
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
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Study name Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Drake et al., 1998 -0.735 0.138 0.019 -1.006 -0.465 -5.328 0.000
Essock et al., 2006 -0.141 0.078 0.006 -0.295 0.012 -1.808 0.071
Morse et al., 2006 -0.368 0.114 0.013 -0.592 -0.144 -3.221 0.001
Barrowclough et al., 2010 -0.592 0.078 0.006 -0.745 -0.440 -7.630 0.000
-0.450 0.135 0.018 -0.715 -0.185 -3.333 0.001
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
Meta Analysis
 
 
 
 
 
 
 
 
 
 
 
20 
 
Reference List 
Baeza, I., Graell, M., Moreno, D., Castro-Fornieles, J., Parellada, M., González-Pinto, A., Payá, 
B., Soutullo, C., de la Serna, E., Arango, C., 2009. Cannabis use in children and adolescents 
with first episode psychosis: Influence on psychopathology and short-term outcome 
(CAFEPS study). Schizophrenia Research 113(2-3), 129-137. 
Baker, A., Bucci, S., Lewin, T.J., Kay-Lambkin, F.J., Constable, P.M., Carr, V.J., 2006. Cognitive-
behavioural therapy for substance use disorders in people with psychotic disorders: 
Randomised controlled trial. British Journal of Psychiatry 188, 439-448. 
Baker, A., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R., Sly, K., Devir, H., Terry, M., 
2002. Evaluation of a motivational interview for substance use with psychiatric in-patient 
services. Addiction 97, 1329-1337. 
Barrowclough, C., Haddock, G., Wykes, T., Beardmore, R., Conrod, P., Craig, T., Davies, L., 
Dunn, G., Eisner, E., Lewis, S., Moring, J., Steel, C., Tarrier, N., 2010. Integrated motivational 
interviewing and cognitive behavioural therapy for people with psychosis and comorbid 
substance misuse: Randomised controlled trial. British Medical Journal 341, c6325. 
Bellack, A.S., Bennett, M., Gearon, J.S., Brown, C.H., Ye Yang, M.S., 2006. A randomized 
clinical trial of a new behavioral treatment for drug abuse in people with severe and 
persistent mental illness. Archives of General Psychiatry 63, 426-432. 
Bonsack, C., Manetti, S.B., Favrod, J., Montagrin, Y., Besson, J., Bovet, P., Conus, P., 2011. 
Motivational intervention to reduce cannabis use in young people with psychosis: A 
randomized controlled trial. Psychotherapy and Psychosomatics 80, 287-297. 
Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., 2005. Comprehensive Meta-Analysis, 2 
ed. Biostat, Englewood, NJ. 
Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., 2009. Introduction to meta-analysis. 
Wiley, Chichester. 
21 
 
Burman, S., 1997. The challenge of sobriety: Natural recovery without treatment and self-
help groups. Journal of Substance Abuse 9, 41-61. 
Calsyn, R.J., Yonker, R.D., Lemming, M.R., Morse, G.A., Klinkenberg, W.D., 2005. Impact of 
assertive community treatment and client characteristics on criminal justice outcomes in 
dual disorder homeless individuals. Criminal Behaviour and Mental Health 15, 236-248. 
Caspari, D., 1999. Cannabis and schizophrenia: Results of a follow-up study. European 
Archives of Psychiatry and Clinical Neuroscience 249, 45-49. 
Castle, D.J., Ho, V., 2003. Substance use in psychosis: What can be done about it? Psychiatry, 
Psychology and Law 10, 144-148. 
Clark, R.E., 2001. Family support and substance use outcomes for persons with mental 
illness and substance use disorders. Schizophrenia Bulletin 27, 93-101. 
Craig, T.K.J., Johnson, S., McCrone, P., Afuwape, S., Hughes, E., 2008. Integrated care for co-
occurring disorders: Psychiatric symptoms, social functioning, and service costs at 18 
months. Psychiatric Services 59, 276-282. 
Drake, R.E., McHugo, G.J., Clark, R.E., Teague, G.B., Xie, H., Miles, K., Ackerson, T.H., 1998. 
Assertive community treatment for patients with co-occurring severe mental illness and 
substance use disorder: A clinical trial. American Journal of Orthopsychiatry 68, 201-215. 
Drebing, C.E., Van Ormer, E.A., Krebs, C., Rosenheck, R., Rounsaville, B., Herz, L., Penk, W., 
2005. The impact of enhanced incentives on vocational rehabilitation outcomes for dually 
diagnosed veterans. Journal of Applied Behavior Analysis 38, 359-372. 
Edwards, J., Elkins, K., Hinton, M., Harrigan, S.M., Donovan, K., Athanasopoulos, O., 
McGorry, P.D., 2006. Randomized controlled trial of a cannabis-focused intervention for 
young people with first-episode psychosis. Acta Psychiatrica Scandinavica 114, 109-117. 
22 
 
Essock, S.M., Mueser, K.T., Drake, R.E., Covell, N.H., McHugo, G.J., Frisman, L.K., Kontos, N.J., 
Jackson, C.T., Townsend, F., Swain, K., 2006. Comparison of ACT and standard case 
management for delivering integrated treatment for co-occurring disorders. Psychiatric 
Services 57, 185-196. 
Green, B., Kavanagh, D.J., Young, R.M., 2007. Predictors of cannabis use in men with and 
without psychosis. Addictive Behaviors 32, 2879-2887. 
Haddock, G., Barrowclough, C., Tarrier, N., Moring, J., O'Brien, R., Schofield, N., Quinn, J., 
Palmer, S., Davies, L., Lowens, I., McGovern, J., Lewis, S., 2003. Cogitive-behavioural therapy 
and motivational intervention for schizophrenia and substance misuse: 18-month outcomes 
of a randomised controlled trial. British Journal of Psychiatry 183, 418-426. 
Hellerstein, D.J., Rosenheck, R.N., Miner, C.R., 1995. A prospective study of integrated 
outpatient treatment for substance-abusing schizophrenic patients. American Journal of 
Addictions 4, 433-442. 
Hellerstein, D.J., Rosenthal, R.N., Miner, C.R., 2001. Integrating services for schizophrenia 
and substance abuse. Psychiatric Quarterly 72, 291-306. 
Herman, S.E., BootsMiller, B., Jordan, L., Mowbray, C.T., Brown, W.G., Deiz, N., Bandla, H., 
Solomon, M., Green, P., 1997. Immediate outcomes of substance use treatment within a 
state psychiatric hospital. The Journal of Mental Health Administration 24, 126-138. 
Hides, L., Dawe, S., Kavanagh, D.J., Young, R., 2006. Psychotic symptom and cannabis relapse 
in recent onset psychosis. British Journal of Psychiatry 189, 137-143. 
Hjorthøj, C.R., Baker, A., Fohlmann, A., Nordentoft, M., 2014. Intervention efficacy in trials 
targeting cannabis use disorders in patients with comorbid psychosis systematic review and 
meta-analysis. Current Pharmaceutical Design 20, 2205-2211. 
23 
 
Hjorthøj, C.R., Fohlmann, A., Larsen, A.-M., Gluud, C., Arendt, M., Nordentoft, M., 2013. 
Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients 
with cannabis use disorder and psychosis: The CapOpus randomized trial. Psychological 
Medicine 43, 1499-1510. 
Hjorthøj, C.R., Fohlmann, A., Nordentoft, M., 2009. Treatment of cannabis use disorders in 
people with schizophrenia spectrum disorders - A systematic review. Addictive Behaviors 34, 
520-525. 
James, W., Preston, N.J., Koh, G., Spencer, C., Kisely, S.R., Castle, D.J., 2004. A group 
intervention which assists patients with dual diagnosis reduce their drug use: A randomized 
controlled trial. Psychological Medicine 34, 983-990. 
Kavanagh, D.J., Mueser, K.T., 2007. Current evidence on integrated treatment for serious 
mental disorder and substance misuse. Journal of the Norwegian Psychological Association 
44, 618-637. 
Kavanagh, D.J., Young, R., White, A., Saunders, J.B., Wallis, J., Shockley, N., Jenner, L., Clair, 
A., 2004. A brief motivational intervention for substance misuse in recent-onset psychosis. 
Drug and Alcohol Review 23, 151-155. 
Lambert, M., Conus, P., Lubman, D.I., Wade, D., Yuen, H., Moritz, S., Naber, D., McGorry, 
P.D., Schimmelmann, B.G., 2005. The impact of substance use disorders on clinical outcome 
in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica 112, 141-148. 
Lehman, A.F., Herron, J.D., Schwartz, R.P., Myers, C.P., 1993. Rehabilitation for adults with 
severe mental illness and substance use disorders: A clinical trial. The Journal Of Nervous 
And Mental Disease 181, 86-90. 
Madigan, K., Brennan, D., Lawlor, E., Turner, N., Kinsella, A., O'Connor, J.J., Russell, V., 
Waddington, J.L., O'Callaghan, E., 2013. A multi-center, randomized controlled trial of a 
24 
 
group psychological intervention for psychosis with comorbid cannabis dependence over 
the early course of illness. Schizophrenia Research 143, 138-142. 
Martino, S., Carroll, K.M., Nich, C., Rounsaville, B.J., 2006. A randomized controlled pilot 
study of motivational interviewing for patients with psychotic and drug use disorders. 
Addiction 101, 1479-1492. 
Morrens, M., Dewilde, B., Sabbe, B., Dom, G., De Cuyper, R., Moggi, F., 2011. Treatment 
outcomes of an integrated residential programme for patients with schizophrenia and 
substance use disorder. European Addiction Research 17(3), 154-163. 
Morse, G.A., Calsyn, R.J., Klinkenberg, W.D., Helminiak, T.W., Wolff, N., Drake, R.E., Yonker, 
R.D., Lama, G., Lemming, M.R., McCudden, S., 2006. Treating homeless clients with severe 
mental illness and substance use disorders: Costs and outcomes. Community Mental Health 
Journal 42(4), 377-404. 
Rebgetz, S., Hides, L., Kavanagh, D.J., Dawe, S., Young, R.M., 2014. A prospective study of 
natural recovery from cannabis use in early psychosis. European Journal of Psychiatry 4, 
218-229. 
Rebgetz, S., Kavanagh, D.J., Hides, L., 2015a. Can exploring natural recovery from substance 
misuse in psychosis assist with treatment? A review of the current research. Addictive 
Behaviors 46, 106-112. 
Rebgetz, S., Kavanagh, D.J., Hides, L., 2015b. Systematic analysis of changes in cannabis use 
among control conditions. Addictive Behaviors Reports 1, 76-80. 
Ries, R.K., Dyck, D.G., Short, R., Srebnik, D., Fisher, A., Comtois, K.A., 2004. Outcomes of 
managing disability benefits among patients with substance dependence and severe mental 
illness. Psychiatric Services 55, 445-447. 
25 
 
Robinson, S.M., Sobell, L.C., Sobell, M.B., Leo, G.I., 2014. Reliability of the Timeline 
Followback for cocaine, cannabis and cigarette use. Psychology of Addictive Behaviors 28, 
154-162. 
Sigmon, S.C., Higgins, S.T., 2006. Voucher-based contingent reinforcement of marijuana 
abstinence among individuals with serious mental illness. Journal of Substance Abuse 
Treatment 30(4), 291-295. 
Smeerdiijk, M., Keet, R., Dekker, N., van Raaij, B., Krikke, M., Koeter, M., De Haan, L., 
Barrowclough, C., Schippers, G., Linszen, D.H., 2012. Motivational interviewing and 
interaction skills training for parents to change cannabis use in young adults with recent 
onset schizophrenia: A randomized controlled trial. Psychological Medicine 42, 1627-1636. 
United Nations Office on Drugs and Crime, 2014. World Drug Report. United Nations, New 
York. 
Wade, D., Harrigan, S., Edwards, J., Burgess, P.M., Whelan, G., McGorry, P.D., 2006. Course 
of substance misuse and daily tobacco use in first-episode psychosis. Schizophrenia 
Research 81, 145-150. 
Weiss, R.D., Griffin, M.L., Kolodziej, M.E., Greenfield, S.F., Najavits, L.M., Daley, D.C., Doreau, 
H.R., Hennen, J.A., 2007. A randomized trial of integrated group therapy versus group drug 
counseling for patients with bipolar disorder and substance dependence. The American 
Journal of Psychiatry 164, 100-107. 
Wisdom, J.P., Manuel, J.I., Drake, R.E., 2011. Substance use disorder among people with 
first-episode psychosis: A systematic review of course and treatment. Psychiatric Services 
62, 1007-1012. 
 
26 
 
Appendix A. Days of cannabis or other substance use in the past 30 days, in control groups of substance use treatment trials in psychotic 
samples at baseline and follow up  
 Substance Baseline 6 months 10-12 months 24 months 
  N M SD N M SD N M SD N M SD 
Drake et al., 19981  S  40 12.5  8.7  40  7.6  8.2  40  7.9  9.1  40  6.3  8.1 
Edwards et al., 20062 C  24 7.8  8.5  24  5.6  9.2       
Essock et al., 20061 S  99 8.1  9.5  99  6.8  9.4  99  5.8  8.4  99  6.8  8.8 
Morse et al., 20063 S/C  49 3.2  3.2  49  2.1  2.5  49  2.5  2.7  49  2.1  2.6 
Barrowclough et al., 20104 S/C 163 21.9  8.2 148 18.1 11.5 137 17.6 11.2 117 15.4 11.9 
Morrens et al., 2011 S/C  35 5.5  2.1  10  4.3 2 .9   7  4.8  2.6    
Smeerdijk et al., 20123 C  27 17.6 10.7     20 13.4 11.0    
Madigan et al., 2013  C  29 10.1  3.6     14 10.1  4.0    
Weighted means              
       Studies to 6 months   13.2   10.6        
       Studies to 10-12 months   13.5      10.6     
       Studies to 24 months   14.3         9.3  
Conversion formulae from reported means (M) to give days of use in the past 30 days:  (1) Days used in past 6 months: M/6; (2) % days used in 
past 4 weeks: M x 30; (3) Days used in past 90: M/3; (4) Proportion of days abstinent from main substance in past 90: (1-M)*30. 
 
